Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Is Neuromuscular Electrical Stimulator Treatment in Sepsis/ Septic Shock Patients Protective in the Development of Intensive Care Unit Acquired Muscle Weakness (ICU-AW)?
Authors not listed
Ondokuz Mayıs University · 2018
Abstract
Background: Sarcopenia (muscle weakness) characterized by a decrease in muscle mass, strength and performance is a condition that increases with old age. Sarcopenia can be seen in 5-13% of patients hospitalized in ICU where various treatment methods are used to prevent this weakness, the rate increases in patients with sepsis/ septic shock. Muscle treatment methods are used to prevent sarcopenia in similar patients hospitalized in ICU. It is predicted that "neuromuscular electrical stimulator-NMES" treatment may increase muscle mass and strength in patients who's can not be exercised actively. In this study, the contribution of NMES treatment to prevent the development of muscle weakness in patients with a diagnosis of sepsis/ septic shock followed in intensive care units (ICU) was evaluated.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-11 MST
Cite this
APA
Anonymous. (2018). Is Neuromuscular Electrical Stimulator Treatment in Sepsis/ Septic Shock Patients Protective in the Development of Intensive Care Unit Acquired Muscle Weakness (ICU-AW)?. <em>Ondokuz Mayıs University</em>. https://clinicaltrials.gov/study/NCT04833621
Vancouver
Anonymous. Is Neuromuscular Electrical Stimulator Treatment in Sepsis/ Septic Shock Patients Protective in the Development of Intensive Care Unit Acquired Muscle Weakness (ICU-AW)?. Ondokuz Mayıs University. 2018.
BibTeX
@misc{anon2018IsNeur,
title = {Is Neuromuscular Electrical Stimulator Treatment in Sepsis/ Septic Shock Patients Protective in the Development of Intensive Care Unit Acquired Muscle Weakness (ICU-AW)?},
author = {Anonymous},
journal = {Ondokuz Mayıs University},
year = {2018},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Ondokuz Mayıs University 2021
Open access · US-GOV
USG evaluatıon of COVID-19 Related Muscle Mass Change in the ICU
Brugmann University Hospital 2018
Open access · US-GOV
Improvement of Sarcopenia in Sarcopenia Patients Following Two Different Diets
AHS Cancer Control Alberta 2014
Open access · US-GOV
A Phase II Double Blind Randomized Trial Comparing Standard Dosing Based on Body Surface Area Versus Dosing Based on Personalized Lean Body Mass in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer Receiving First Line Cisplatin Based Chemotherapy
National Taipei University of Nursing and Health Sciences 2024
Open access · US-GOV
The Effectiveness of Lower Extremity Strength Training on the Physical Performance of Patients With Chronic Schizophrenia With Sarcopenia.
Dokuz Eylul University 2023
Open access · US-GOV
Evaluation of Sarcopenia and Associated Factors in Patients With Lipedema
Nanjing Medical University 2021
Open access · US-GOV